302440.KS
SK bioscience Co.,Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 37,750.00
+0.80%Year over year
Reported trailing growth
- Revenue
- +23.2%
- EBITDA
- —
- EBIT
- -9.7%
- EPS
- -57.5%
- Free cash flow
- +22.4%
- Operating cash flow
- -48.0%
Forward estimates
Based on analyst estimates
- Revenue
- +6.2%
- EBITDA
- +156.6%
- EPS
- +34.2%
Three-year CAGR
- Revenue
- +12.6%
- EBITDA
- -66.6%
- EBIT
- -9.3%
- Net income
- -4.3%
- EPS
- -2.6%
- Free cash flow
- +73.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026